NCT06863493View on ClinicalTrials.gov

Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

September 1, 2026

Conditions

Psoriasis (PsO)

Interventions

DRUG

SFA002

SFA002 760mg

DRUG

Otezla

Oral Otezla 30mg

DRUG

Placebo

Placebo will be matched to whichever drug is assigned when randomized

Sponsors

Lead Sponsor

SFA Therapeutics

All Listed Sponsors

lead

SFA Therapeutics

INDUSTRY

NCT06863493 - Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients | Biotech Hunter | Biotech Hunter